Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ - Friday, March 14, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on March 13, 2024 to the following person discharging managerial responsibilities were vested on March 13, 2025:-
| Award Holder |
| Number of ordinary shares |
| | | |
| Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer) | | 19,913 |
The notification set out below is provided in accordance with the requirements of the UK Market Abuse Regulation.
Dr Weiguo Su
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Dr Weiguo Su | ||||
| 2 | Reason for the notification | |||||
|
a) |
Position/status |
Executive Director, Chief Executive Officer and Chief Scientific Officer
| ||||
|
b) |
Initial notification/Amendment
|
Initial notification
| ||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name
|
HUTCHMED (China) Limited | ||||
|
b)
|
LEI |
2138006X34YDQ6OBYE79 | ||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of US$0.10
Ordinary Share with DI ISIN: KYG4672N1016 | ||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on March 13, 2024 under HUTCHMED's LTIP
| ||||
|
c) |
Price(s) and volume(s) |
| ||||
|
d) |
Aggregated information
|
N/A | ||||
|
e) |
Date of the transaction |
2025-03-13
| ||||
|
f) |
Place of the transaction |
Outside a trading venue
| ||||
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception, HUTCHMED has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| | |
| Media Enquiries | |
| FTI Consulting - | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Alex Shaw | +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
| Brunswick - Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| | |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Freddy Crossley / Rupert Dearden | +44 20 7886 2500 |
| | |
| HSBC | Joint Broker |
| Simon Alexander / Alina Vaskina / Arnav Kapoor | +44 20 7991 8888 |
| | |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
